Inclusion Criteria:  Must fall into one of the three categories defined as high risk of developing pancreatic cancer:  High Risk Group 1 (familial pancreatic cancer relatives):  older than 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and Have 2 or more family members with a history of pancreatic cancer, and Have a first-degree relationship with at least one of the relatives with pancreatic cancer.  High Risk Group 2 (Has gene mutation(s) with an associated with an estimated lifetime risk of pancreatic cancer of approximately 10% or higher):  50 years old and has FAMMM (p16/CDKN2A) gene mutation. older than 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and Has known BRCA2, Acute Transverse Myelopathy (ATM), partner and localizer of BRCA2 (PALB2) gene mutation, and There is more than 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.  High Risk Group 3 (Has gene mutation(s) with an associated with an estimated lifetime risk of pancreatic cancer of approximately 5%):  Older than 55 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and Has known BRCA1, or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, postmeiotic segregation 1(PMS1), human MutS homolog 6 (hMSH6), EpCAM) gene mutations, and There is more than 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug. Ability to understand and willingness to sign a written informed consent document. Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol. Men must use acceptable form of birth control while on study.  Exclusion Criteria:  If expected to require any other form of systemic or localized antineoplastic therapy while on study.  Within 4 weeks prior to first dose of study drug.  o Any systemic or topical corticosteroids at immunosuppressive agents.  Within 4 weeks prior to first dose of study drug.  Any investigational device. Has received a live vaccine. Received any allergen hyposensitization therapy. Any major surgery. Infection with HIV or hepatitis B or C. Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements monoclonal antibody. Has a diagnosis of immunodeficiency. Any other sound medical, psychiatric, and/or social reason as determined by the Investigator. Unwilling or unable to follow the study schedule for any reason. Are pregnant or breastfeeding.